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Abstract
The precise mechanisms leading to the emergence of low-level glycopeptide resistance in Staphylococcus aureus are poorly
understood. In this study, we used whole genome deep sequencing to detect differences between two isogenic strains: a
parental strain and a stable derivative selected stepwise for survival on 4 mg/ml teicoplanin, but which grows at higher drug
concentrations (MIC 8 mg/ml). We uncovered only three single nucleotide changes in the selected strain. Nonsense
mutations occurred in stp1, encoding a serine/threonine phosphatase, and in yjbH, encoding a post-transcriptional negative
regulator of the redox/thiol stress sensor and global transcriptional regulator, Spx. A missense mutation (G45R) occurred in
the histidine kinase sensor of cell wall stress, VraS. Using genetic methods, all single, pairwise combinations, and a fully
reconstructed triple mutant were evaluated for their contribution to low-level glycopeptide resistance. We found a
synergistic cooperation between dual phospho-signalling systems and a subtle contribution from YjbH, suggesting the
activation of oxidative stress defences via Spx. To our knowledge, this is the first genetic demonstration of multiple sensor
and stress pathways contributing simultaneously to glycopeptide resistance development. The multifactorial nature of
glycopeptide resistance in this strain suggests a complex reprogramming of cell physiology to survive in the face of drug
challenge.
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Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) infections is a
major cause of morbidity and mortality worldwide, including in the
health care setting. The mortality rate associated with invasive
MRSA infections is significant and in the United States MRSA
infections are now quoted as the leading cause of death by an
infectious agent [1]. MRSA infections are particularly difficult to
treat because of the development of antibiotic resistance and limited
therapeutic options. Glycopeptide antibiotics (vancomycin and
teicoplanin) are still the preferred drugs for treatment of serious
hospitalorcommunity-acquiredMRSAinfections,despitereportsof
increasing numbers of glycopeptide-resistant MRSA isolates [2,3].
Glycopeptide resistance in Staphylococcus have emerged by two
mechanisms. Highly glycopeptide-resistant S. aureus strains (VRSA;
MIC$16 mg/ml) acquired the exogeneous multigene VanA
complex carried on transposon Tn1546 from Enterococcus faecalis
by horizontal gene transfer. Fortunately, these events are infrequent
and only few examples are known worldwide [4,5]. The second
mechanism of resistance, termed endogenous or low-level (MICs
with .2 mg/ml to ,16 mg/ml), arises because spontaneous
mutation(s) are thought to confer a selective survival advantage.
Endogeneous resistance is thought to occur stepwise: emergence of
resistance to low-antibiotic levels must be first acquired to allow
growth in progressively higher antibiotic concentrations [6,7]. The
exact molecular mechanism(s) leading to endogeneous resistance to
teicoplanin, or vancomycin, is/are unknown. A common resistance
pathway has being suggested since in general reduced susceptibility
to vancomycin strains also display reduced teicoplanin sensitivity.
However, teicoplanin resistance can be acquired without alteration
in vancomycin susceptibility [3,6].
Endogenous resistance is more often observed and clinical
studies have linked glycopeptide clinical failure with progressive
selection of bacterial isolates showing increasing glycopeptide
resistance levels. In some reported cases, as little as a two-fold
change in MIC altered clinical outcome [8,9]. Such concerns have
resulted in the recent re-evaluation of clinical breakpoints for
glycopeptides [10] (www.srga.org/). In light of these concerns,
understanding the molecular changes permitting survival of S.
aureus during drug challenge is of paramount importance.
Glycopeptides are non-penetrating cell wall acting antibiotics
whose site of action lies outside the cell membrane, implying that
changes in physical-chemical barriers, detection, signalling and
response mechanisms could conceivably promote resistance.
Several phenotypic responses leading to resistance are observed in
some, but not all cases and include thicker cell wall, reduced
autolysisand increasedcellwallcrosslinking[11,12,13,14,15,16,17].
These changes are thought to be correlated with a differential
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studies, point mutations occurring in only one gene (vraRS, graRS or
tcaA) have been described and confirmed by genetic analysis to
contribute to glycopeptide resistance [15,18,19]. No studies
concerning the functional links between these pathways have been
provided, however. Only one study has uncovered multiple
mutations by sequence analysis when comparing Mu50 (VISA)
and a revertant Mu50V (VSSA) that were conclusively proven to
contribute to low-level glycopeptide resistance [20].
In this study, we identified genomic changes using whole
genome deep sequencing of a teicoplanin-susceptible and its
teicoplanin-resistant derivative. Point mutations occurred in three
genes and complete genetic analysis proved their causal link to
glycopeptide resistance. We demonstrate multiple pathways
contributing to glycopeptide resistance emergence including two
types of phosphosignalling (histidine and serine/threonine)
combined with a global redox/thiol stress sensor.
Results
Genomic sequencing of isogenic ISP794 and AR376
strains
To identify genomic changes selected during teicoplanin
exposure, whole genome deep sequencing of both ISP794 and
AR376 was performed. AR376 is an in vitro derived stable
teicoplanin-resistant mutant from laboratory strain ISP794 [21].
Since ISP794 and AR376 are derivatives of the sequenced
NCTC8325 strain (NCBI Accession No. NC_007795), we used this
as a reference to evaluate genome coverage and facilitate contig
assembly. Using Illumina-Solexa technology, we obtained 5,659,670
and 3,609,916 of 35-bp paired-end reads for ISP794 and AR376
strains, respectively, mapping the reference genome. The raw
coverage depth was 35 and 23 times for ISP794 and AR376,
respectively. Mapping covered 2,819,664 and 2,819,622 bases in
ISP794 and AR376 strains, resulting in 99.8% and 99.6% of
NCTC8325 genome coverage (2,821,361 bp), respectively. Most of
the reference genome was covered sufficiently (minimum coverage of
3 read bases per reference base) to allow single nucleotide
polymorphism (SNP) detection. The paired end information was
used to detect with high confidence insertions and deletions (InDel).
SNP and InDel differences detected between ISP794 and
AR376 strains
Computeranalysisofinterstraindifferencesbetweentheassembled
ISP794 and AR376 genomes first revealed 9 potential SNPs and 11
potential InDels. Each difference was subsequently re-examined by
genomic DNA PCR amplification using appropriate primers and
sequencing. Six potential SNPs and all InDel differences were
rejected by this analysis. As shown in Figure 1, only 3 SNP differences
apparently distinguished AR376 from its parental strain ISP794.
SNPs were detected in three different open reading frames
corresponding to reference sequence tag SAOUHSC 00938,
Figure 1. Genomic differences detected by whole genome sequencing. (A) Chromosomal location of detected SNPs and predicted protein
changes. (B) Physical map of each locus containing yjbH(K23stop), stp1(Q12stop) and vraS(G45R). For genetic analysis, each mutation was tagged by
site-specific insertion of a nearby selectable marker to facilitate strain constructions using bacteriophage-mediated transduction.
doi:10.1371/journal.pone.0021577.g001
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N315 ordered sequence tags SA0860, SA1062 and SA1701,
respectively). Similarity searches with SAOUHSC 00938 indicated
the presence in Bacillus subtilis of a gene showing partial similarity
and annotated as yjbH (SwissProt accession BG13137). In B. subtilis
YjbH is an adaptor protein, which, together with ClpXP protease,
regulates the degradation of the global transcriptional regulator
Spx [22]. In S. aureus, YjbH is a hypothetical protein showing 34%
identity and 73% amino acid sequence similarity with YjbH of B.
subtilis. The yjbH t/a SNP occurred at nucleotide position 67
generating a nonsense mutation at amino acid 23 (K23stop). The
SAOUHSC 01186 gene encodes Stp1, a serine/threonine
phosphatase [23]. The stp1 c/t SNP occurred at nucleotide
position 34 generating a nonsense mutation at amino acid 12
(Q12stop). Finally, the SAOUHSC 02099 gene encodes the
histidine kinase sensor VraS. The vraS c/t SNP occurred at
nucleotide position 133 generating a missense mutation at amino
acid 45 by substituting arginine for glycine (G45R) (Figure 1). The
amino acid G45 in VraS is located in a region predicted to lie
between two N-terminal transmembrane domains suggesting a
possible role in extracellular signal sensing.
Genetic analysis of each SNP and its contribution to
teicoplanin-resistance
To determine whether each individual SNP detected in AR376
contributed to reduced teicoplanin susceptibility, we first re-
engineered each SNP change by site-specific mutation or phage
mediated transduction backcross in ISP794 (see Table 1). As judged
by broth macrodilution MICs and confirmed by spot population
analysis profiles (spot PAP assays), vraS(G45R), or stp1(Q12stop), led to
reduced teicoplanin susceptibility (MIC=2 mg/ml) compared to the
parent ISP794 (MIC=1 mg/ml) (Table 2). Spot PAP assays revealed
detectably enhanced growth of both single mutants on MHA
supplemented with increasing concentrations of teicoplanin, while
no growth was observed with parent ISP794. Identical results were
obtained when comparing a second independent isolate of each single
mutant (Figure 2A). In contrast to vraS(G45R) and stp1(Q12stop)
mutants, a small increase of growth was observed for yjbH(K23stop)
while no growth was observed for the parent ISP794. Growth was
observed when 1610
5 and 1610
4 colony forming units were applied
on MHA supplemented with 0.5 mg/ml of teicoplanin (Figure 2A).
However, MIC analysis showed no difference between ISP794 and its
isogenic yjbH(K23stop) mutant (MIC=1 mg/ml) (Table 2).
Complementation of either vraS(G45R) or stp1(Q12stop) mutants
by a multicopy plasmid carrying the corresponding wild-type genes,
led to restored sensitivity to teicoplanin (Figure S1). As yjbH(K23-
stop) mutation has a subtle effect on teicoplanin resistance,
complementation of the yjbH mutation was performed by
introducing a multicopy plasmid carrying yjbH wild-type gene into
the triple mutant (see below), a condition where its role could be
readily assessed. We observed restored sensitivity of the triple
mutant to levels comparable with the double mutant vraS(G45R)/
stp1(Q12stop) mutant (Figure S1).
Collectively, we conclude that single vraS (G45R), stp1 (Q12stop)
and, to a lesser extent, yjbH(K23stop) mutations in parent ISP794
decreased teicoplanin susceptibility, however, none of the single
mutations alone could account for the parental AR376 MIC levels.
We conclude that some combination of these mutants must
therefore contribute to the observed teicoplanin-resistant pheno-
type of AR376.
Effect of mutant combinations on teicoplanin resistance
We next analysed the drug resistance phenotypes of each of the
three possible pairwise mutants: stp1/yjbH, stp1/vraS, and yjbH/
vraS. As shown in Figure 2B and Table 2, a further decrease of
teicoplanin susceptibility was observed only with double mutant
vraS(G45R)-stp1(Q12stop). Spot PAP assays revealed growth of the
double vraS(G45R)-stp1(Q12stop) mutant on MHA supplemented
with 2 mg/ml teicoplanin and showing a macrodilution MIC of
4 mg/ml. Notably, the double mutant displayed enhanced growth
compared to either of the single mutants alone (Figure 2A and B,
compare growth and log10 –fold scale, teicoplanin 1 mg/ml panels,
for the single stp1 or vraS mutants versus the stp1/vraS double
mutant). In contrast, and as detected by spot PAP assay and
macrodilution MIC, the other two pairwise mutants did not show
any decrease in teicoplanin susceptibility (Figure 2B and Table 2).
Interestingly, the decrease in teicoplanin susceptibility observed in
vraS(G45R), or stp1(Q12stop) single mutants, was abolished by the
yjbH(K23stop) mutation (Figure 2A, B and Table 2). These results
suggest that the loss of yjbH exerts a negative effect on the
pathways leading to drug sensitivity changes engendered by
vraS(G45R) or stp1(Q12stop) mutations.
Although the double mutant vraS(G45R)-stp1(Q12stop) de-
creased teicoplanin susceptibility, it still did not fully recapitulate
the AR376 MIC levels. The effect on teicoplanin susceptibility of
the fully reconstructed triple mutant was therefore tested. Genetic
analysis of the re-engineered triple mutant revealed complete
restoration of the teicoplanin resistance phenotype indistinguish-
able from AR376. Spot PAP assays revealed identical growth of
both the triple mutant vraS(G45R) - stp1(Q12stop) - yjbH(K23stop)
and AR376 on MHA supplemented with increasing concentra-
tions of teicoplanin (Figure 2B) and identical macrodilution MIC
levels were also observed (MIC=8 mg/ml) (Table 2).
Effect of single mutations and their combinations on
vancomycin susceptibility
The impact of all mutations was also examined for their
contribution to changes in vancomycin susceptibility, despite the
fact that the in-vitro derived teicoplanin-resistant AR376 strain
showed only a 2-fold marginal increase in vancomycin MIC
compared to its susceptible counterpart ISP794 (Table 2). Changes
in vancomycin MICs were not as dramatic as the changes
observed in teicoplanin MICs for the various mutant combinations
(Table 2). Nevertheless, as shown in Figure 2C, similar results with
teicoplanin susceptibilities were observed using the more sensitive
log10-scaled growth assay. Spot PAP assays revealed detectable
enhanced growth of both single vraS(G45R) or stp1(Q12stop)
mutants on MHA supplemented with 1 mg/ml of vancomycin
compared to the susceptible strain ISP794. In contrast no
difference was observed with yjbH(K23stop) mutant. At 2 mg/ml
vancomycin concentration only AR376 showed growth and
comparable colony formation as observed with control agar plates
with no drug. Further analysis of all pairwise and triple mutants
revealed a detectable decrease in vancomycin susceptibility only
for the double vraS(G45R)-stp1(Q12stop) and reconstructed triple
mutants. As previously noted above and in results presented in
Figure 2B, we also observed that the yjbH(K23stop) mutation,
when paired with either vraS(G45R) or stp1(K12stop) exerted a
negative effect by reversing drug sensitivity changes arising from
these single mutations.
Taken together, we conclude that all three SNPs were
collectively responsible for the decreased glycopeptide susceptibil-
ity of AR376 strain. Furthermore, vraS(G45R) and stp1(Q12stop)
mutations acted synergistically to reduce glycopeptide susceptibil-
ity while yjbH(K23Stop) contributed significantly to low level
glycopeptide resistance in this strain only when paired with the
dual phospho-signalling mutants. These results also reveal that
although AR376 was originally selected for reduced susceptibility
Glycopeptide Resistance in S. aureus
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susceptibility, albeit to a lesser degree in this strain background.
The sensitivity of the spot PAP assay to reveal these subtle changes
underscores its powerful application to unravelling the genetics of
endogenous glycopeptide resistance.
Analysis of cell wall thickness by electron microscopy
Since the VraRS two-component sensor system regulates a
response to cell wall stress and controls, in part, the expression of
genes involved cell wall metabolism [24], and further, since stk1/
stp1 modulate cell wall metabolism [25], we analysed the cell wall
thickness of all strains used in this study by transmission electron
microscopy (Figure 3). As reference control strains, we first
analysed the cell wall thickness of the glycopeptide resistant strain
Mu50, which displays a significantly thicker cell wall (50.468 nm)
than the glycopeptide susceptible control strain ATCC29213
(17.3562.9 nm) (Figure 3A and 3B; [11]). Analysis of AR376
showed a significantly (p,0.001) thicker cell wall compared to its
susceptible counterpart ISP794 and furthermore, this enhanced
thickness was comparable to, and in fact greater than, Mu50. Both
Table 1. Strains and plasmids used in this study.
Strain/plasmid Revelant genotype Characteristics
Source/
reference
S. aureus
RN4220 8325-4; r- m+, restriction defective laboratory strain [55]
ISP794 8325 pig 131 [56]
AR376 ISP4-2-1 21
AR774 vraS (G45R) ISP794, vraS (G45R) kan
r nearby This study
AR758 kan
r nearby vraS ISP794, vraS kan
r nearby 32
AR756 vraS::ermB ISP794, vraS::ermB 32
AR802 kan
r nearby stp1(Q12stop) AR376, stp1(Q12stop) kan
r nearby This study
AR860 kan
r nearby stp1 ISP794, stp1kan
r nearby This study
AR826 stp1 (Q12stop) ISP794, stp1(Q12stop) kan
r nearby This study
AR853 tetK
r nearby stp1(Q12stop) AR376, stp1(Q12stop) tetK
r nearby This study
AR858 vraS (G45R), stp1 (Q12stop) ISP794, vraS (G45R) kan
r nearby, stp1(Q12stop) tetK
r nearby This study
AR864 vraS (G45R), yjbH (K23stop) AR376, stp1 kan
r nearby This study
AR854 stp1 (Q12stop), yjbH (K23stop) AR376, vraS kan
r nearby This study
AR1077 ery
r nearby yjbH (K23stop) AR376, yjbH (K23stop) ery
r nearby This study
AR1079 yjbH (K23stop) ISP794, yjbH(K23stop) ery
r nearby This study
AR1082 vraS (G45R), yjbH (K23stop), stp1 (Q12stop) ISP794, vraS (G45R) kan
r nearby, yjbH (K23stop)
ery
r nearby, stp1(Q12stop) tetK
r nearby
This study
AR964 AR774/pAM1483 This study
AR1001 AR826/pAR992 This study
AR1085 AR1082/pAR973 This study
SaDclpP 8325-4 derived strain clpP deleted strain [57]
Dspx 8325-4 derived strain spx deleted strain 27
spx
+ 8325-4 Dspx, Pspx-spx::geh spx deleted strain and chromosomally complemented
with the intact copy of spx inserted into geh locus.
27
Plasmids
pTYB12 N-terminal fusion IMPACT intein and chitin binding domain plasmid New England
(Biolabs)
pMK4 E.coli-S.aureus shuttle vector, amp
r and cam
r [58]
pBT2 E.coli-S.aureus thermosensitive-shuttle vector, amp
r and cam
r [59]
pBluescript II KS+ routine multicopy E.coli cloning vector amp
r Stratagene
pAR749 pBT2, vraS-G45R kan
r nearby ts shuttle vector This study
pAR712 pBT2, vraS-kan
r-SA1699 intergenic ts shuttle vector 32
pAR784 pBT2, stp1-kan
r nearby ts shuttle vector This study
pAR787 pBT2, stp1-tet
r nearby ts shuttle vector This study
pAR1063 pBT2, yjbH-ery
r nearby ts shuttle vector This study
pAM1483 pMK4- 3.3 kb entire vraR operon and upstream promoter region Kpn-Pst 32
pAR992 pMK4- containing Not1-Kpn pHU promoter region, Kpn-Pst1 Stp1 gene This study
pAR973 pMK4- containing Not1-Kpn pGlyS promoter region, Kpn-Pst1 yjbH gene This study
pAM1101 pTYB12-SpxA (Nde-Pst) This study
doi:10.1371/journal.pone.0021577.t001
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cantly increased (p,0.001) cell wall thickness compared to the
susceptible parental strains ISP794, while in contrast, no
significant difference was observed between vraS(G45R) mutant
and ISP794. Analysis of all pairwise mutants showed a significantly
greater (p,0.001) increase in cell wall thickness compared to
ISP794; however, no double mutation attained AR376 cell wall
thickness levels. Indeed, the observed mean thickness for both the
stp1/vraS and stp1/yjbH mutations were significantly less (p,0.001)
than AR376. Only the fully reconstituted triple mutant AR1082
showed comparable cell wall thickness as AR376 strain. It is
worthwhile noting that the yjbH(K23stop) mutation enhanced cell
wall thickness when paired with either stp1(Q12stop) or vraSG45R
in these assays in contrast to the negative effect of yjbH(K23stop)
on teicoplanin MIC and spot PAP assay growth (on either
teicoplain or vancomycin) when paired with these mutants as
described above. Apart from these changes in cell wall thickness,
we did not observe overt changes in cell division such as aberrant
septum formation or other peculiar morphology for any mutation
examined.
Collectively, these results show that all mutations contribute to
significant alterations in cell wall thickness in our strain
background; however, the observed changes in cell wall thickness
do not precisely correlate with the observed changes in
glycopeptide susceptibility. We conclude that changes in glyco-
peptide sensitivities in this strain background must arise primarily
from physiological changes other than pronounced changes in cell
wall thickness.
YjbH negatively regulates Spx levels in S. aureus
A role for YjbH has not been previously described in S. aureus;
however, in B. subtilis, YjbH acts as a post-transcriptional negative
regulator of the global oxidative/thiol stress regulator Spx [26].
YjbH binds Spx and functions as an adaptor protein directing
ClpXP-dependent degradation of Spx. Disruption of yjbH or clpP
in B. subtilis is known to result in enhanced levels of Spx since its
proteolytic turnover is greatly attenuated. A rise in Spx levels leads
to substantial changes in gene expression profiles.
To address the hypothesis that S. aureus YjbH acts as a negative
regulator of Spx analogous to its B. subtilis counterpart, we first
examined Spx protein levels by western blot. As shown in Figure 4,
rabbit polyclonal anti-Spx antibody recognized purified S. aureus
Spx migrating with the expected molecular weight of 15 kDa. No
Spx was detected in a negative control S. aureus 8325-4 derived
strain extract containing an internal disruption of spx, whereas Spx
was strongly detected in cell extract lacking clpP as previously
described [27]. Spx was also detected in an extract from AR376,
harbouring the triple vraS(G45R)-stp1(Q12stop)-yjbH(K23stop)
mutant combination. Importantly, comparison of extracts from
ISP794 and its isogenic derivative AR1079 containing the
yjbH(K23Stop) mutation, showed that Spx was undetectable in
the presence of wild type yjbH, but clearly detectable in the
presence of the yjbH(K23Stop). We conclude from these results
that the loss of yjbH results in significant stabilization of Spx
protein in S. aureus and that YjbH probably functions similarly to
its B. subtilis counterpart by aiding Spx proteolytic turnover.
Consequently, the triple mutant AR376 harbors changes in two
distinct phosphosignalling pathways and possesses enhanced Spx
protein levels arising from the loss of its negative regulator yjbH.
Influence of Spx and teicoplanin on transcription of
msrA1 encoding methionine sulfoxide reductase in S.
aureus
Several lines of evidence link oxidative stress and S. aureus
responses to glycopeptide antibiotics. First, recent work suggests
that the mode of killing by several classes of antibiotic, including
glycopeptides, involves the endogenous production of reactive
oxygen radicals [28]. Secondly, transcriptional profiling revealed
that an oxidative stress defence gene, msrA1, encoding methionine
sulfoxide reductase was among those genes most strongly up-
regulated in response to variouscell wall active antibiotics,including
glycopeptides, in S. aureus [29,30]. As msrA1 transcription is known
to be positively regulated by Spx in B. subtilis [31], we hypothesized
that a possible functional consequence of the loss of yjbH in AR376,
would be enhanced transcription of Spx-dependent genes such as
msrA1 (N315 ordered sequence tag SA1257). To explore this
possibility, we tested whether msrA1 was indeed subject to Spx-
dependent transcription regulation in S. aureus.
The results (Figure 5A) show that in a Dspx strain, teicoplanin
exposure resulted in no significant induction of msrA1 compared to
uninduced control, whereas in the Dspx strain complemented with
a chromosomally integrated copy of wild type spx, msrA1 induction
was significantly induced more than 3-fold (p,0.05) following
exposure to teicoplanin. Indeed, in the absence of spx, even basal
msrA1 transcript levels were significantly lower (p,0.05) compared
with msrA1 transcript levels in the spx complemented strain.
Since the yjbH(K23stop) mutation results in significant stabili-
zation of Spx protein, we also analysed whether the steady state
msrA1 transcription in the absence of drug induction was affected
in either AR376 or the yjbH(K23stop) single mutant. Figure 5B
shows that basal msrA1 transcript levels were indeed significantly
higher (p,0.05) in both AR376 and yjbH(K23stop) mutant
compared to the parental strain ISP794. We conclude from these
results that msrA1 is subject to transcriptional regulation dependent
upon spx in S. aureus.
We also recently described the discovery of trfA (teicoplanin
resistance factor A) as a gene whose loss restores glycopeptide
sensitivity in AR376 [21]. We have found that trfA transcript levels
are also significantly increased by the loss of yjbH and that the
trfA promoter is also positively regulated by Spx (A. Renzoni,
manuscript in preparation). Taken together, these findings
strongly suggest that stabilization of Spx through disruption of
yjbH results in important functional consequences within the cell
since Spx positively regulates the expression of at least two genes,
msrA1 and trfA, known to contribute to glycopeptide resistance.
Table 2. Glycopeptide susceptibility profiles of ISP794 and its
derivatives.
MIC
* mg/ml
Strain Teicoplanin Vancomycin
ISP794 1 2
AR376 8 4
vraS
* 22
stp1
* 22 – 4
yjbH
* 12
vraS
*/stp1
* 44
vraS
*/yjbH
* 12
stp1
*/yjbH
* 12
vraS
*/stp1
*/yjbH
* 84
*MIC, Modal minimum inhibitory concentration measured by broth
macrodilution. VraS
*, stp1
* and yjbH
* correspond to vraS (G45R), stp1
(Q12stop) and yjbH (K23stop) mutations, respectively.
doi:10.1371/journal.pone.0021577.t002
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(A and B) Teicoplanin spot plating population analysis (Spot PAP) on teicoplanin of ISP794 and each of its strain derivatives. Spot serial dilutions are
indicated at the right margin. The first spot 10 ml corresponds to 1610
5 colony forming units (CFU). Results for two independent isolates are shown
for each single mutant (solid bar). For convenience, genes are marked with an asterisk such that vraS*, stp1* and yjbH* correspond to vraS(G45R),
stp1(Q12stop) and yjbH(K23stop) mutations, respectively. (C) Vancomycin spot plating population analysis (Spot PAP) of ISP794 and each of its strain
derivatives. Conditions used were as in panels A, B.
doi:10.1371/journal.pone.0021577.g002
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PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e21577Figure 3. Cell wall thickness analysis. (A) Transmission electron microscopy showing one representative image of each bacterial strain used in
this study, after growth in the absence of antibiotic to post-exponential phase on TSB media. Magnification637,000. Scale bar automatically inserted
by the microscope imaging system is shown. (B) Quantification of cell wall thickness (nm) of each bacterial strain. Reported values correspond to the
mean 6 SD (n=at least 40) of each bacterial strain. Asterisk (*) represents results significantly different by student’s two-tailed t-test (p,0.05) from
ISP794.
doi:10.1371/journal.pone.0021577.g003
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vraS(G45R) or spx mutations on the emergence
teicoplanin resistance in S. aureus
Since AR376 was originally obtained by stepwise cultivation on
agar plates containing low levels of teicoplanin we wished to
determine the extent to which each individual mutation identified
in our study contributed to a change in a detectable frequency of
emergence of teicoplanin resistant colonies using our standard
assay conditions [21,32]. In light of our findings that disruption of
yjbH altered Spx levels, we also tested the effect of spx deletion in
the same assay. The results are shown in Table 3.
Compared to ISP794, strains harboring any of the three
mutations, stp1(Q12Stop), yjbH(K23Stop) or vraS(G45R) - each
backcrossed by bacteriophage mediated transduction into ISP794
and never having been previously exposed to glycopeptides,
resulted in strongly enhanced frequency (from 4- to 10-fold) of
emergence of low-level teicoplanin resistant colonies on MH agar
plates. In contrast, loss of spx was associated with at least a 10-fold
reduction in the frequency of emergence of teicoplanin resistant
colonies compared to the identical strain background harboring a
second wild-type copy of spx. We conclude that loss of spx reduced
the emergence of teicoplanin resistant colonies while mutation in
any of the three mutations discovered by genomic sequence
analysis of AR376 enhanced the emergence of teicoplanin
resistance.
Discussion
In the present study, we show by deep sequencing and genetic
analysis that a laboratory selected low level teicoplanin interme-
diate resistant S. aureus strain has only three point mutations which
distinguished it from its parental susceptible strain. These changes
occur in two distinct (histidine kinase and serine/threonine kinase)
phospho-signalling systems and in a gene contributing to a global
oxidative/thiol stress defence response pathway. Moreover, we
present evidence revealing a synergistic interaction between the
dual phospho signalling pathways. The contribution of the third
mutation in yjbH is subtle, and its properties suggest that it most
probably exerts its effect following the first step acquisition of low
level glycopeptide resistance mediated by the combined effects of
stp/vraS mutations.
S. aureus glycopeptide resistance has been often correlated with
morphological changes such as increased cell wall thickness,
peptidoglycan crosslinking or decreased autolysis. Both vraS and
stp1 are known to affect cell wall metabolism, although precisely
how is unknown [23,24,33,34,35].
The VraRS two-component system (TCS) responds to cell-wall
active antibiotics [24,33]. Under cell wall stress, expression of vraRS
and several cell wall biosynthetic genes are strongly upregulated.
Disruption of the histidine kinase vraS gene blocks this transcrip-
tional response and reduces ß-lactam or glycopeptide resistance
levels [32,33,36] Missense mutations in vraS altering the suscepti-
bility to glycopeptides are commonly observed [17,20,37,38].
How vraS(G45R) contributes to enhanced glycopeptide resis-
tance is unknown. Amino acid 45 is located in the short region
predicted to span two putative transmembrane segments and
suggests a role in signal detection. The G45R mutation could also
conceivably affect interaction with other regulatory proteins. For
example, B. subtilis LiaF, a membrane protein, is thought to
negatively regulate LiaS, a putative S. aureus VraS ortholog. B.
subtilis LiaF is syngenic to S. aureus SA1702, and mutations in
SA1702 have also been reported to affect glycopeptide resistance
[17,38]. Indeed, a recent report suggests that S. aureus SA1702/
Figure 4. Western blot showing the effect of yjbH(K23stop)
mutation on Spx protein levels. Total soluble protein extracts
(50 mg) from S. aureus strains were loaded per well in an SDS 15%
acrylamide gel. Spx protein (15 kDa) was detected using rabbit-
polyclonal anti-Spx antibodies. Purified-Spx protein (600 ng) (lane 1),
Dspx strain (lane 2), ISP794 containing wild-type yjbH gene (lane 3), yjbH*
correspond to yjbH(K23stop) mutant (lane 4), SaDclpP strain (lane 5) and
AR376 (lane 6). The position of protein markers are shown in the right
margin.
doi:10.1371/journal.pone.0021577.g004
Figure 5. Effect of spx on msrA1 transcription. (A) Steady-state
levels of msrA1 transcript of wild type strain (spx
+) compared to mutant
Dspx strain, determined by qRT-PCR. Values represent the mean 6 SEM
of four independent experiments performed in triplicate. Data are
depicted setting spx
+ values in the absence of teicoplanin as 100%.
Asterisk (*) represents results significantly different by student’s two-
tailed t-test (p,0.05) from spx
+ without teicoplanin. (B) Steady-state
levels of msrA1 transcript of ISP794 containing wild-type yjbH gene,
AR376 and yjbH* containing both yjbH(K23stop) mutation, determined
by qRT-PCR. Values represent the mean 6 SEM of three independent
experiments performed in triplicate. Data are depicted setting ISP794
values as 100%. Asterisk (*) represents results significantly different by
student’s two-tailed t-test (p,0.05) from ISP794.
doi:10.1371/journal.pone.0021577.g005
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SA1702/YvqF may modulate VraS signalling and detection of cell
wall stress [39].
The vraS(G45R) mutation does not detectably increase VraR
operon mRNA levels compared to its isogenic parent strain, or any
gene (sgtB, prsA, htrA1, murZ) thought to be regulated by VraR that
we tested by qRT-PCR and our experimental conditions.
Nevertheless, this mutation by itself does result in pronounced
changes in emergence of glycopeptide resistance frequencies. This
result is curious, since in most reported cases, glycopeptide
resistant bacteria show increased expression of vraR operon
transcription compared to susceptible parental strains [24,37,40].
Nevertheless, one report, consistent with our findings, showed that
increased transcription of vraS or vraRS operon is not essential for
acquisition of low-level glycopeptide resistance [41]. A closer study
of vraR operon regulation and VraR phosphorylation mechanisms
is warranted to resolve precisely how VraS missense mutations
disrupt signalling.
In S. aureus, Stp1 plays a role in phospho-signalling, together
with Stk1 [23,34,35,42,43]. Stp1 (N315-SA1062), encodes a
manganese-dependent serine/threonine phosphatase, capable of
dephosphorylating Stk1 [23,34]. Stk1 is thought to be a membrane
protein which possesses three extracellular PASTA domains
(penicillin-binding protein and serine/threonine kinase associated
domain) [44]. Stk1 or Stp1 have been shown to have a role in S.
aureus virulence, cell wall metabolism and antibiotic resistance (for
review see [25]). The effects of a single stp1 mutant, however, have
not been tested for glycopeptide resistance [23,34,35,42,43]. To
our knowledge, our work is the first study to report mutation in
stp1 alone directly affecting glycopeptide resistance levels.
It is not known how stk1/stp1-mediated signalling contributes to
the detection of antibiotic encounter and orchestration of cellular
responses. One plausible hypothesis is that Stk1 senses some
feature(s) of the cell wall assembly process via its PASTA domains
and phosphorylates multiple downstream factors that coordinate
proper assembly and quality control [44]. In the event of
encounter with cell wall active drugs such as glycopeptides, Stk1
could conceivably signal damage and initiate a cascade of
signalling events that permit survival in the face of drug stress.
The loss of function of stp1 would have the predictable
consequence of enhancing the duration of substrates phosphory-
lated by Stk1. Stk1 and Stp1 are only beginning to be understood
in S. aureus, however. To date, several Stp1 client substrates have
been described including the global accessory regulator SarA,
MgrA, and the nucleoid organizing protein HU [43,45]. MgrA is
known to be a major cell-wall autolytic regulator which modulates
antibiotic resistance, including glycopeptides [45], providing a
possible mechanistic link between signal systems and altered cell
wall assembly.
Changes in cell wall thickening resulting from stp1 disruption
appear to be strain dependent and divergent results have been
reported for strains Newman and N315, for example [23,34,43].
The reason for these discrepancies is unknown and additional
studies will be needed to resolve this important issue. The
stp1(Q12stop) mutation present in our strain background nearly
doubled cell wall thickness compared to ISP794. A recent
metabolome study using 8325, a strain closely related to ISP794,
detected striking coordinate increases in peptidoglycan intermedi-
ates depending upon the sequential action of MurA to MurF
enzymes in a strain lacking stp1 compared to its isogenic parent
[46]. These results strongly suggest that stk1/stp are indeed
intimately involved in the regulation of cell wall biosynthesis.
A striking feature of our study is the enhanced glycopeptide
resistance of the double stp1(Q12stop)/vraS(G45R) mutation
compared to the resistance levels of the single mutants alone.
This observation suggests the intriguing possibility that these
signalling systems collaborate to modulate genes necessary to elicit
drug resistance. Understanding the molecular mechanism of
endogenous glycopeptide resistance arising from this dual
signalling synergy is being vigorous pursued.
The yjbH(K23stop) mutation displays both positive and negative
effects upon glycopeptide resistance. By itself, the yjbH(K23stop)
mutation displays little contribution to glycopeptide resistance,
whereas when combined as a double mutant with either the
vraS(G45R) or stp1 null mutation, yjbH(K23stop) mutation reduces
resistance. These findings suggest that mutation of yjbH exerts a
negative influence on endogenous glycopeptide resistance achieved
with either phosphosignalling pathway mutant alone. In contrast,
when yjbH mutation is combined with the double mutant
stp1(Q12stop)/vraS(G45R), a two-fold increase in modal teicoplanin
Table 3. Effect of the single point mutations and spx on the emergence of teicoplanin resistance.
No. bacteria under
non-selective conditions T0
No. bacteria under
selective conditions T2
Frequency of
emergence
1
Strain Relevant genotype Mean (n=7) SEM Mean (n=7) SEM T2/T0 %
ISP794 ISP794, rsbU
2 7.82610
+7 2.01610
+7 255 79 3.26610
26 100
3
AR1079 ISP794, yjbH(K23stop) ery
r nearby 6.98610
+7 1.95610
+7 895 201 1.28610
25 394
AR774 ISP794, vraS(G45R) kan
r nearby 1.25610
+7 2.24610
+6 .1000
2 8.00610
25 .1000
AR826 ISP794, stp1(Q12stop) kan
r nearby 2.80610
+7 5.73610
+6 .1000
2 3.50610
25 .1000
Mean (n=5) SEM Mean (n=5) SEM
spx+ 8325-4Dspx, Pspx-spx::geh 1.59610
+8 1.61610
+7 .1000
2 .6.00610
26 100
4
Dspx 8325-4Dspx 1.05610
+8 1.39610
+7 49 12 4.70610
27 ,10
1Frequency of emergence expressed as the ratio of colony forming units (CFU) under selective (Teicoplanin 2 mg/ml) and non-selective conditions (No teicoplanin).
Colony forming units were counted at 48 h, 37uC.
2Viable counts on agar containing 2 mg/ml of teicoplanin were too high to accurately measure using these conditions. More than 1000 CFU were estimated in each
experiment.
3The effect of rsbU
+ on glycopeptide emergence is discussed in Galbusera et al (30). ISP794 emergence frequency was set equal to 100% for normalization and
comparison.
4The emergence frequency was set equal to 100% for normalization and comparison with its derivative Dspx.
doi:10.1371/journal.pone.0021577.t003
Glycopeptide Resistance in S. aureus
PLoS ONE | www.plosone.org 9 June 2011 | Volume 6 | Issue 6 | e21577MIC was observed (4 to 8 mg/ml) and was accompanied by
increased colony counts indistinguishable from the parental triple
mutant sequenced strain AR376. In this instance, yjbH clearly acts
positively. The negative effects due to yjbH(K23stop) were also
observed with vancomycin although its positive contribution to
reduced susceptibility to this drug was less apparent in both spot
PAP assays and modal MIC values. Future research will resolve in
detail how YjbH and Spx contribute to glycopeptide resistance.
The drug resistance profiles of the three mutations detected in
our study suggest that their temporal appearance was hierarchical.
If either signalling mutation had occurred first, followed by yjbH,
then the results we provide upon genetic reconstruction suggest
little or no possibility for growth of the yjbH(K23stop)/stp1 or
yjbH(K23stop)/vraS(G45R) mutation on teicoplain 2 mg/ml and
thus little chance for continued selection. In contrast, it is
reasonable to assume that the dual signalling mutants emerged
first, followed by the acquisition of the yjbH mutation. This genetic
order has the effect of pushing the teicoplanin MIC from 4 mg/ml
to 8 mg/ml. It is thus tempting to speculate that the effect of yjbH,
either by itself, or more likely through Spx, is manifest only when a
threshold pre-existing level of glycopeptide resistance is attained.
We have shown that loss of yjbH leads to stabilization of Spx
protein levels and provide evidence that Spx modulates the
expression of at least two genes (msrA1 and trfA) involved in
glycopeptide resistance. Spx is necessary for the upregulation of
msrA1, encoding methionine sulfoxide reductase, an enzyme
required to combat oxidative stress. msrA1 (SA1257) is transcribed
as a four-gene operon (SA1254-SA1257) and induced by several
cell wall active antibiotics [24,29,30,33]. In addition, activating
oxidative stress defences is a plausible strategy to combat antibiotic
stress since recent studies reveal that several antibiotics, including
glycopeptides, kill cells by promoting the production of endoge-
nous reactive oxygen species [28,47,48].
Teicoplanin resistance factor A, encoded by trfA, is also regulated
by YjbH and Spx (A. Renzoni, manuscript in preparation). TrfA is
important for glycopeptide resistance in several strain backgrounds
including AR376 used in this and other studies, although its precise
function has yet to be established [21]. Studies are underway to
dissect which precise pathways are affected by the trfA mutation.
The three mutations uncovered in our study each contribute to
enhanced cell wall thickness, although vraS(G45R) evokes only
minimal change by itself and acts in conjunction with either of the
other mutations. These findings could partly explain the reduced
glycopeptide sensitivites observed in some, but not all of our
strains, since in many instances no change in glycopeptide MICs
were detected despite strong changes in cell wall thickness. To
date, the majority of clinical glycopeptide resistant strains exhibit
cell wall thickening [3,11]; however, reduced susceptibility to
glycopeptides can be achieved without alterations in cell wall
thickness [49,50]. Other metabolic changes must be affected by
the mutations uncovered in our study which modulate low level
glycopeptide resistance. While herein we present a detailed
analysis suggesting an intricate interplay among signalling
pathways in one particular strain, it is certainly possible that
additional genes and pathways contributing to the acquisition of
endogeneous glycopeptides resistance will be uncovered.
Materials and Methods
Bacterial strains and culture conditions
Bacterial strains used in this study are listed in Table 1. The
NCTC8325 strain ISP794 (MIC=1 mg/ml) and its teicoplanin-
derivative AR376 (MIC=8 mg/ml) are MLST type ST8 (3-3-1-1-
4-4-3) and were described previously [21]. All S. aureus and E. coli
strains were grown in Mueller-Hinton broth (MHB) and Luria-
Bertani medium, respectively. When required, media were
supplemented with the following antibiotics: 15 mg/ml chloram-
phenicol, 5 mg/ml erythromycin, 40 mg/ml kanamycin, and 3 mg/
ml tetracycline.
Genome sequencing
Genomic DNA (gDNA) was prepared from an overnight culture
grown in MHB at 37uC as previously described [21]. Solexa
technology was used to sequence the genomic DNA of both
ISP794 and AR376 strains on an Illumina Genome Analyzer
GAII (Illumina; Fasteris, SA, Geneva, Switzerland). The quality-
controlled filtered reads, followed by alignment to the reference
sequence NCTC8325 strain, were used to generate a consensus
sequence for both ISP794 and AR376 strains, using the IUPAC
ambiguity code. The generated consensus ISP794 and AR376
sequences were then compared to detect SNPs and InDel
differences. All detected SNPs and InDels were subsequently
verified or rejected by PCR of relevant genomic DNA and
capillary sequencing. Additional details are available upon request.
Construction and analysis of genetic point mutants
To test the contribution of each individual mutation to
glycopeptide resistance, or reconstruct all possible combinations,
we used genetic linkage analysis by conveniently tagging each
mutation with a nearby resistance marker (Figure 1B), using pBT2
thermosensitive plasmid [21]. All plasmids were first electroporat-
ed into non-restricting strain RN4220 prior to electroporation into
ISP794 and its derivative strains. After growth with applied
marker selection at a non-permissive temperature for pBT2
replication, double cross-over events were screened using antibi-
otic markers and all linked mutants were confirmed by PCR and
sequencing. We also verified in every case that the insertion of the
antibiotic-resistant marker alone did not alter the susceptibility
phenotype to either teicoplanin or vancomycin. The intergenic
regions chosen were devoid of known small regulatory RNAs.
While we cannot exclude that the markers used confer some
changes to the cell which we do not detect, they are importantly
neutral with respect to all assays used in this study to measure
glycopeptide susceptibility. All antibiotic-linked SNP mutations
were subsequently backcrossed to ISP794 using bacteriophage
W80a-mediated generalized transduction. In some cases, allelic
exchange using nearby markers linked to the wild type locus were
used to remove one or several point mutations and restoration of
wild type sequence. Non-cell wall active antibiotic selectable
markers kanamycin, tetracycline, and erythromycin were obtained
as previously described [21,32]. Details of the construction of each
single, pairwise, or reconstituted triple mutation are indicated
below. In no case did we observe that single, double mutants, or
the reconstructed triple mutant displayed altered growth rates or
detectable fitness changes compared to ISP794.
Generation of point mutant vraS(G45R) in ISP794
VraS(G45R) point mutation linked to a kanamycin-resistant
marker was constructed in ISP794 as follows: a chromosomal
fragment containing a nucleotide change in position 133 (C to T)
of vraS open-reading frame (ORF) to generate an amino acid
change from glycine to arginine, was amplified from ISP794 using
primers described in Table S1. A restriction site (Bgl2) was used to
ligate a kanamycin resistance marker at position 1972957 (NCTC
8325 genome sequence coordinates).
The resulting plasmid, pAR749, was electroporated into
vraS::ermB mutant (described in [32] selecting for kanamycin
resistance. Double cross-over events were screened on agar
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15 mg/ml chloramphenicol and 5 mg/ml erythromycin plates to
screen for chloramphenicol and erythromycin-sensitive but
kanamycin-resistant colonies. Clone AR774a was selected and
used to backcross vraS(G45R) linked to kanamycin resistant marker
to ISP794 using W80a lysates. A single mutant vraS(G45R) clone,
AR774, was retained for further study.
Generation of stp1(Q12stop) and yjbH(K23stop) single
mutants in ISP794
A similar strategy was used to generate stp1(Q12stop) mutant in
ISP794 strain. We first pre-marked strain AR376 by targeted
insertion of a kanamycin resistance marker nearby the stp1 gene
(chromosomal locations 1142731 and 1142744 from NCTC 8325
genome sequence coordinates), using primer pairs described in
Table S1. A restriction site (Bgl2) was used to insert a kanamycin
resistant marker as described above. The resulting plasmid,
pAR784, was electroporated into AR376, selecting with 40 mg/
ml kanamycin and then replica streaked on 15 mg/ml chloram-
phenicol plates to screen for chloramphenicol-sensitive but
kanamycin-resistant colonies. Clone AR802 was chosen and used
to backcross the stp1(Q12stop) linked to kanamycin resistant
marker to ISP794 using bacteriophage generalized transduction
with W80a lysates. A single mutant stp1(Q12stop) AR826 was
retained for further study.
To generate the yjbH(K23stop) mutant, strain AR376 was pre-
marked by targeted insertion of an erythromycin resistance gene
nearby yjbH gene in position 905525 (NCTC 8325 genome
sequence coordinates) using plasmid pAR1063 generated with
primers described in Table S1. One colony was selected and
designated AR1077. Transfer of yjbH(K23stop) mutation into
ISP794 strain was next performed by bacteriophage transduction
using W80a lysates of AR1077 selecting for erythromycin-
resistance marker. A single mutant yjbH(K23stop), AR1079, was
fully verified by PCR and sequence analysis and retained for
further study.
Generation of pairwise and triple mutants
The double mutant vraS(G45R)-stp1(Q12stop) was constructed
as follows: we first pre-marked strain AR376 nearby stp1 gene
(AR853) using plasmid pAR787 as described above, but instead
inserting a tetracycline resistance marker at the same chromo-
somal location as we had inserted the kanamycin marker. Transfer
of the stp1(Q12stop) mutation to vraS(G45R) mutant (AR774) was
next performed by bacteriophage transduction using W80a lysates
of AR853 selecting for the tetracycline-resistance marker. The
selected kanamycin and tetracycline-resistant transductant
(AR858) was analysed for acquisition of both vraS(G45R) and
stp1(Q12stop) mutations by sequencing. The double mutant
vraS(G45R)-yjbH(K23stop) was constructed as follows: we pre-
marked strain ISP794 nearby stp1 gene (AR860) using plasmid
pAR784 as described above, but instead inserting a kanamycin
resistance marker. Transfer of the stp1 wild-type gene to AR376
was next performed by bacteriophage transduction using W80a
lysates of AR860 selecting for the kanamycin-resistance marker.
The selected kanamycin-resistant transductant (AR864) was
analysed for acquisition of wild-type stp1 gene by allelic exchange
and the presence of both vraS(G45R) and yjbH(K23stop) mutations
by sequencing. To construct the double mutant stp1(Q12stop)-
yjbH(K23stop), we pre-marked strain ISP794 with a kanamycin
resistance marker nearby wild-type vraS gene (AR758) using
plasmid pAR712 as previously described [32]. Transfer of wild-
type vraS gene to AR376 was next performed by bacteriophage
transduction using W80a lysates of AR758 selecting for the
kanamycin-resistance marker. The selected kanamycin-resistant
transductant (AR854) was analysed for acquisition of wild-type
vraS gene and the presence of both stp1(Q12stop) and yjbH(K23-
stop) mutations by sequencing.
Finally, to reconstruct the vraS(G45R)-stp1(Q12stop)-yjbH(K23-
stop) triple mutant, we transfered the yjbH(K23stop) mutation from
AR376 by bacteriophage transduction using W80a lysates of
AR1077 to the double mutant vraS(G45R)-stp1(K23stop) (AR858)
selecting for the erythromycin-resistance marker. The selected
erythromycin, kanamycin and tetracycline-resistant transductant
(AR1082) was analysed for acquisition of vraS(G45R), stp1(Q12stop)
and yjbH(K23stop) mutations by sequencing.
Plasmids for complementation
Plasmid pMK4 was used to express the entire wild-type vraR
operon under control of its own promoter and stp1 or yjbH under
the control of the heterologous pHU or pGlyS promoters (Table 1).
Briefly, pMK4 plasmid containing Not1-Kpn pGlyS or pHU
promoters were obtained as described [51,52]. PCR fragments
containing vraR operon, or promoterless stp1 or yjbH were cloned
into Kpn-Pst1 restriction sites using primers described in Table S1.
All constructions were sequenced verified. Plasmids constructed
in E. coli were first introduced into strain RN4220 prior to
transformation of the corresponding mutant strains. Plasmids for
negative controls in these experiments were either empty pMK4,
or pMK4 harboring a heterologous gene, namely GFPuv4, driven
by the same pHU or pGlyS promoters.
Minimal inhibitory concentration (MIC) and population
analysis
Broth macrodilution MIC assays were performed in triplicate as
previously described according to CLSI (Clinical and Laboratory
Standards Institute) standard procedures [21]. Results were
reported as the modal MIC values. The spot PAP method was
used to assess population analysis, as previously described [21,32].
Bacterial cultures were adjusted to 0.5 MacFarland standard
(1.5610
8 bacteria/ml), corresponding to an OD600=0.1. Serial
log10 dilutions (resulting in a range 10
21 to 10
25) were prepared,
then aliquots of each dilution (10 ml) were spotted on freshly
prepared MH agar (MHA) containing different concentrations of
teicoplanin or vancomycin. Viable colonies were examined after
48 h at 37uC. The results reported were consistant across at least
five independent assays. It is important to emphasize that the MIC
values reported throughout our studies were determined using
broth macrodilution; this method may give higher values than
other susceptibility testing methods. Indeed, a recent study
conducted in our laboratory indicates that microdilution methods
tend to underestimate glycopeptide resistance [53].
Purification of recombinant Spx protein and antibody
production
The open reading frame of the spx gene (SA0856 N315) was
PCR amplified with primers indicated in Table S1 and cloned in
pBluescriptII KS+. A sequenced verified spx fragment was next
subcloned into E. coli expression vector pTYB12 (New England
Biolabs) using Nde1-Pst1 sites, generating plasmid pAM1101. N-
terminal intein-recombinant Spx protein was then purified using
chitin affinity column (IMPACT system, New England Biolabs) as
follows: E. coli strain ER2566 (New England Biolabs) containing
pTYB12-Spx protein was grown in Luria-Bertani media contain-
ing carbenicillin at 100 mg/ml until an OD600 of 0.7, induced with
0.4 mM isopropyl–b-D-1-thiogalactopyranoside (IPTG) for an
additional 2 h30 min at 22uC with vigorous shaking. Bacteria
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containing 0.1% Tween 20, followed by affinity chromatography
and intein-mediated proteolytic cleavage of the affinity tag with
50 mM DTT. Recombiant Spx protein was eluted with 20 mM
Tris-HCl pH 7.5, 500 mM NaCl and 1 mM EDTA, according to
the manufacturer’s recommendations. Thiol-induced intein cleav-
age resulted in the N-terminal attachment of three additional
amino acids AlaGlyHis. Protein concentrations were determined
using Bradford reagent (BioRad) and a bovine serum albumin
standard. Recombinant Spx protein was stored at 4uC and used
to generate polyclonal antibodies using the Rabbit Express
TM
extended protocol (Pickcell Laboratories, Netherlands).
Western blot analysis
Total protein extracts were obtained as follows: 10 ml of an
overnight culture of S. aureus strains in MHB were harvested. After
centrifugation, cell pellets were washed and resuspended in 500 uL
TES (10 mM Tris pH 7.5, 1 mM EDTA and 0.1% SDS).
Bacterial cells were disrupted by adding 500 ml of acid washed
glass beads (100–200 micron, Sigma) and using FastPrep cell
disrupter (MP Biomedicals). The cell debris were separated from
soluble protein extracts by centrifugation for 10 min at 4uCa t
17000 rpm (JA-20 rotor Beckman) followed by a second
centrifugation step to remove additional insoluble and aggregated
proteins (30 min, 4uC, 17000 rpm). Supernatant was removed and
proteins were concentrated on Amicon spin columns (4 kDa cut-
off, Milian, Geneva, Switzerland). Protein concentrations were
determined by Bradford assay (Bio-Rad). Aliquots of total proteins
(50 mg) were loaded on 15% SDS-PAGE gels and blot transferred
onto a polyvinylidene difluoride membranes (PVDF, Bio-Rad).
After blocking using 5% (w/v) low fat milk in phosphate buffered
saline, membranes were probed with a 1:1500 dilution of Spx
antibody followed by incubation with a secondary HRP-
conjugated goat anti-rabbit antibody (1:10,000 BioRad). Chemi-
luminescence was detected using the Western Pico Super Signal
reagent (Pierce).
Assays for emergence of teicoplanin resistance
Emergence of glycopeptide resistance was performed as
previously described [21,32]. Overnight bacterial cultures were
adjusted to McFarland 2.0 in 0.9% NaCl and ca. 3610
8 CFU/
ml were plated on Muller Hinton agar (BD BBL 211438)
containing the indicated freshly prepared teicoplanin concentra-
tion and incubated for 48 h at 37uC. To determine the frequency
of emergence, serial dilutions of each culture were also plated on
MHB plates without drug. Results are expressed as the mean 6
SEM of seven independent experiments for ISP794, AR774,
AR826, AR1079 and five independent experiments for spx+ and
Dspx. A subset of colonies was retested by replica plating on
selective agar plates to estimate the percentage of false positives
(persisters cells which score as susceptible upon replating on
selective medium) arising in each experiment. False positive rate
of CFUs detected in the emergence assay were found to be 5–
20% depending upon the experiment. The raw data are reported
without correction and thus calculated emergence frequencies
represent an upper limit. ISP794 used in this study is defective in
rsbU. The effects of this mutation, its restoration, and the role of
sigB in the emergence of teicoplanin resistance in this strain
background have been thoroughly addressed in our previous
study [32].
Total RNA extraction
Overnight cultures of 8325-4spx-c and 8325-4Dspx were diluted
and grown at 37uC for 4 h in MHB without shaking. When
indicated, sub-inhibitory concentrations of teicoplanin (0.5 mg/ml)
were added and incubated for an additional hour. Bacteria were
harvested and RNA extraction was performed as previously
described [21]. The absence of contaminating DNA was verified
by PCR using qRT-PCR probes in the absence of reverse
transcription.
Quantitative real-time qRT-PCR
mRNA levels were determined by quantitative RT-PCR (qRT-
PCR) using the one-step reverse transcriptase qPCR Master Mix
Kit (Eurogentec, Seraing, Belgium) as described [54]. Primers and
probes were designed using PrimerExpress software (version 1.5;
Applied Biosystems), and obtained from Eurogentec. MsrA1
primers (from SA1257) and probe are: msrA1-334F 59GGAAG-
TAACCTCTGGATCAAACGT, MsrA1-415R 59CCCTACT-
TATGAACAGGTATGTACGAAT and msrA1-359T 59ATTTG-
TACTGCTTCGACATGGCCGGTT. 16S primers and probe
are described [54]. Reverse transcription and PCR were
performed using primers and probes at a concentration of 0.2
and 0.1 mM, respectively. The msrA1 mRNA levels were
normalized on the basis of their 16S rRNA levels, which were
assayed in each round of qRT-PCR as internal controls as
described [54].
Transmission electron microscopy
S. aureus strains were grown on TSB at 37uC under shaking
conditions until post-exponential phase. One milliter of post-
exponential phase bacteria was pelleted by low speed centrifuga-
tion, washed with PBS and fixed for 30 min in PBS containing 4%
(v/v) glutaraldehyde. Fixed cells were further treated with 2%
osmium tetroxide in buffer and immersed in a solution of 0,25%
uranyl acetate to enhance membrane contrast. The pellets were
dehydrated in increasing concentrations of ethanol followed by
pure propylene oxide, then embedded in Epon resin. Thin sections
for electron microscopy were stained with uranyl acetate and lead
citrate and observed in a Technai 20 electron microscope (FEI
Company, Eindhoven, The Netherlands). Digital images were
captured at 37,0006. Cell wall thickness was determined using
equatorial sections and four independent measurements for each
image from random placement of a cardinal point grid. The
reported values represent the mean of at least 40 independent
images for each strain.
Supporting Information
Figure S1 Complementation of either yjbH(K23stop),
stp1(Q12stop) or vraS(G45R) mutants by multicopy
plasmid carrying wild-type genes. (A) Spot plating popula-
tion analysis of each single mutant and its corresponding
complemented strain on teicoplanin. V* and s* complementation
was tested on teicoplanin containing 0.5 mg/ml. Spot serial
dilutions are indicated at the right margin. As yjbH(23stop)
mutation has a subtle effect on teicoplanin resistance, comple-
mentation of the yjbH mutation was performed by introducing a
multicopy plasmid carrying wild-type yjbH gene into the triple
strain mutant, a condition where its role could be unambiguously
assessed. Y* complementation was tested on teicoplanin contain-
ing 2 mg/ml. For convenience genes marked with an asterisk such
as v*, s* and y* correspond to vraS(G45R), stp1(Q12stop) or
yjbH(K23stop) mutations, respectively.
(TIF)
Table S1 Primers used in this study.
(DOC)
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